Censinet

Deliberate C, and the honest grade for this record. The moat is unambiguously the RISK EXCHANGE NETWORK: more than 1,000 healthcare organisations and over 50,000 vendors and products sharing assessment data, which compounds with participation and cannot be replicated by a model. The company's own framing is that it transforms risk management by leveraging network scale and efficiencies. AI is a 2026 layer on top, with the GRC AI vision described as a roadmap and vision rather than shipped capability, and the FICO-style 300 to 850 inherent risk score is a scoring methodology whose algorithmic basis is not established. Same principle applied to Reveleer, the credentialing lane and Neurotrack: where the asset is the network or dataset rather than the model, AI Centrality is graded down regardless of how the company positions itself. Indexed because the AI capabilities are identifiable and gradeable, the ModMed test.

Assessment and workflow automation feeding human risk decisions, with the platform explicitly adapting to the customer's operating model across three modes: the internal team operating it independently, a co-managed arrangement where Censinet provides Risk Management Services alongside the customer, and the on-demand Censinet One managed-service-enabled model. Being explicit that a customer can choose how much of the work the vendor performs is a clearer statement of the human boundary than most vendors offer. Graded B rather than A because no statement was located on what, if anything, the platform determines without human review, particularly for the automated inherent risk scoring.

The frameworks are named precisely, which is creditable: HSCC Sector Mapping and Risk Toolkit, the 17 critical functions underpinning healthcare delivery, and NIST Cybersecurity Framework support. But the AI itself is described at vision and capability level without technical substance. The FICO-style 300 to 850 risk score is the central quantitative output and no derivation, weighting or validation is published, which matters because a numeric score carries an implied precision that an unexplained methodology does not support. Borrowing the FICO framing invites an inference of comparability and rigour that is not evidenced.

Strong commercial and adoption evidence, no efficacy evidence. Reported scale is substantial and specific at over 1,000 healthcare organisations and more than 50,000 vendors, with named health system investors including MemorialCare, Rex Health Ventures, Ballad Ventures and Cedars-Sinai, and a reported period of 100 percent year-over-year ARR growth with no customer losses. American Hospital Association Preferred Cybersecurity Provider status is meaningful third party endorsement from the sector's own trade body. The company also publishes an annual Healthcare Cybersecurity Benchmarking Study, which is genuine industry research rather than marketing. Graded B rather than A because none of this demonstrates that using the platform reduces breaches, incidents or third-party risk exposure, and no outcome study was located.

The platform is described as a HIPAA-secure risk exchange, and the data it holds is vendor risk assessment content rather than patient records, so the PHI surface is structurally small. The more interesting stewardship question is the exchange model itself: participating organisations share cybersecurity and risk data across a collaborative network, which is the source of the platform's value and also means a health system's own risk posture data sits in a shared environment. No published detail on segregation, anonymisation or what is visible to other participants was located.

Described consistently as a HIPAA-secure platform, and the company operates as a risk and compliance vendor to more than 1,000 healthcare organisations, so HIPAA alignment is core to the offering. Graded B rather than A because no BAA terms were located in published form.

No third party attestation such as SOC 2 Type II or HITRUST was retrieved at the time of review. As with Asimily, this is a sharper gap for a security and risk vendor than for others, since the company's product is assessing exactly this in other vendors.

Not an FDA regulated product. Risk management and GRC tooling sit entirely outside Software as a Medical Device. The relevant regulatory and framework surface is substantial though: HIPAA Security Rule, NIST Cybersecurity Framework, and the HSCC Sector Mapping and Risk Toolkit, which the company states it is the first platform to operationalise.

Graded on an unusual basis, because this vendor sells AI governance rather than only practising it. The AI Telemetry capability provides healthcare organisations with continuous evidence-based visibility into AI exposure across their third-party ecosystem, explicitly to close the gap between AI adoption and AI governance, which is a substantive contribution to the governance problem this index cares about. The irony worth noting is that the company publishes no governance framework for its OWN scoring models, so a platform that monitors customers' AI exposure does not disclose how its own risk scores are produced or validated. Graded B for the product contribution, held back from A by that gap.

No named integrations were located. The relevant integration surface for a GRC and third-party risk platform is procurement, vendor management and ticketing systems rather than clinical systems, and no specific integrations were disclosed in retrieved materials.

Cloud platform with genuinely flexible operating models, which is the notable feature: customers can run it themselves, operate it co-managed with Censinet Risk Management Services, or consume it on demand through Censinet One, described as a managed-service-enabled platform. That range accommodates health systems with very different internal security staffing, which is a real constraint in this market. No data residency disclosure located.

No pricing published and no pricing basis disclosed. The multi-modal delivery structure, spanning self-operated, co-managed and on-demand, implies materially different cost profiles depending on how much service is bundled, and none of that is public. Buyers cannot determine whether they are comparing software cost or software plus managed service cost against alternatives.

Broad across both risk domains and participant types, and distinctly wider than the device-security vendors in this category. Covers third-party risk and enterprise risk, spanning vendors and products from medical devices and cloud software to robotics and consulting services, and serves health systems, health plans and vendors themselves, meaning both sides of the assessment relationship participate in the same exchange. The 2026 additions extend to systemic and concentration risk across 17 sector-defined critical functions, which moves the analysis from individual vendor risk to ecosystem-level dependency, a genuinely different scope from anything else in this lane.